Skip to main
INDV
INDV logo

Indivior PLC (INDV) Stock Forecast & Price Target

Indivior PLC (INDV) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Indivior PLC's patient base for Sublocade treatment increased to approximately 171,500 in the third quarter of 2025, marking an 8% growth compared to the same quarter in 2024. The company has also seen a rise in prescribers of Sublocade, reaching about 8,568, which represents an 11% increase year-over-year. Furthermore, Indivior's upward revision of its 2025 revenue guidance for Sublocade, now estimated at $765 million to $786 million, reflects strong volume growth and the company's strategic focus on expanding its penetration in the Medicaid and commercial patient segments.

Bears say

Indivior PLC faces a challenging financial outlook primarily due to the expected decline in revenue from its key product, Suboxone, as a result of increasing generic competition. Although growth is anticipated from Sublocade in the long-acting injection (LAI) category, the company's overall revenue may not sufficiently offset the losses from Suboxone, especially considering unfavorable projections for subsequent quarters. Additionally, the forecasted selling, general, and administrative expenses (SG&A) will still constitute a significant portion of revenue, suggesting potential operational inefficiencies that could further pressure profitability.

Indivior PLC (INDV) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Indivior PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Indivior PLC (INDV) Forecast

Analysts have given Indivior PLC (INDV) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Indivior PLC (INDV) has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Indivior PLC (INDV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.